Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:13 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 565 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Non-Alcoholic Fatty Liver Disease Clear all

Conditions: Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver
Interventions: OA-235i (4 mg), OA-235i (8 mg), OA-235i (16 mg), OA-235i (30 mg), OA-235i (40 mg), OA-235i or placebo; Drug
Lead sponsor: Oasis Pharmaceuticals, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Nonalcoholic Steatohepatitis
Interventions: SEL, FIR, CILO, Placebo to match FIR, Placebo to match CILO, Placebo to match SEL; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 395 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 81
States / cities: Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 62 more

Conditions: Non-alcoholic Fatty Liver Disease
Interventions: Efimosfermin Alfa, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 57
States / cities: Arcadia, California • Covina, California • Los Angeles, California + 44 more

Conditions: Non-Alcoholic Fatty Liver Disease, Obesity
Interventions: Alternate day fasting, Exercise; Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Obesity, Liver Diseases, Liver Fibrosis, Liver Fat, Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis, MASLD, MASH, Weight Loss, Insulin Resistance, Insulin Sensitivity, Insulin Sensitivity/Resistance, Metabolic Disease, Diabetes, Diabetes Mellitus, Type 2, NASH With Fibrosis, Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver, Non-alcoholic Steatohepatitis
Interventions: ESG + lifestyle modification, Lifestyle modification; Device · Behavioral
Lead sponsor: Pichamol Jirapinyo, MD, MPH; Other
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts • Morgantown, West Virginia

Conditions: Fasting, Non-alcoholic Fatty Liver Disease (NAFLD)
Interventions: Fasting, Diet, oral carbohydrate challenge; Behavioral · Dietary Supplement
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: NASH - Nonalcoholic Steatohepatitis
Interventions: HM15211, Placebo of HM15211; Drug
Lead sponsor: Hanmi Pharmaceutical Company Limited; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 48
States / cities: Huntsville, Alabama • Chandler, Arizona • Chula Vista, California + 37 more

Conditions: Steatohepatitis, Nonalcoholic, Hemosiderosis, Overweight Adolescents, Obesity, Childhood, Liver Steatosis
Interventions: Not listed
Lead sponsor: The Geneva Foundation; Other
Eligibility: 10 Years to 17 Years
Enrollment: 150 participants
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Fort Sam Houston, Texas

Conditions: Non-Alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic, Obesity
Interventions: Mindfulness Based Stress Reduction (MBSR); Behavioral
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Metabolic Syndrome, Nonalcoholic Fatty Liver Disease
Interventions: Sodium Octanoate Breath Test; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Houston, Texas • Richmond, Virginia

Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Interventions: ALN-PNP, Tirzepatide, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 9
States / cities: Tucson, Arizona • Coronado, California • Pasadena, California + 6 more

Conditions: HIV Infections, Coronary Artery Disease, Non-Alcoholic Fatty Liver Disease
Interventions: Not listed
Lead sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine; Other
Eligibility: 18 Years and older
Enrollment: 233 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: San Diego, California

Conditions: Fatty Liver, Hepatic Steatosis, Diabetes Mellitus, Liver Diseases
Interventions: Probiotic-containing powder; Drug
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Metabolic Associated-dysfunction Steatotic Liver Disease (MASLD), Metabolic Associated-dysfunction Steatohepatitis (MASH)
Interventions: Standard of care acceptance-based behavioral weight loss program, Occupational therapy dietary and lifestyle modifications; Behavioral
Lead sponsor: Grand Valley State University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Wyoming, Michigan

Conditions: Non-alcoholic Fatty Liver Disease
Interventions: GSK4532990; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 14
States / cities: Chula Vista, California • Montclair, California • San Diego, California + 8 more

Conditions: Liver Disease
Interventions: Not listed
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 2 Years to 17 Years
Enrollment: 969 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 12
States / cities: San Diego, California • San Francisco, California • Atlanta, Georgia + 9 more

Conditions: Metabolic Dysfunction-Associated SteatoHepatitis (MASH)
Interventions: ALN-HSD, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 61
States / cities: Flagstaff, Arizona • Peoria, Arizona • Tucson, Arizona + 46 more

Conditions: Nonalcoholic Steatohepatitis
Interventions: solithromycin; Drug
Lead sponsor: Melinta Therapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Diabetes Complications, Fatty Liver
Interventions: exenatide; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 70 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Non-alcoholic Fatty Liver Disease
Interventions: Experimental: Low-fructose, reduced carbohydrate diet, General Healthy Diet; Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 11 Years to 17 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Interventions: Vitamin E, Placebo; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 9
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 6 more

Conditions: Fatty Liver
Interventions: Cysteamine; Drug
Lead sponsor: Joel Lavine; Other
Eligibility: 10 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: San Diego, California

Conditions: NASH - Nonalcoholic Steatohepatitis, NAS, Overweight or Obesity, Weight Loss, Bariatric Surgery Candidate
Interventions: Vertical Sleeve Gastrectomy (VSG); Procedure
Lead sponsor: University of Minnesota; Other
Eligibility: 40 Years to 67 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious, Cirrhosis Alcoholic, Cirrhosis Due to Hepatitis C
Interventions: Rosuvastatin; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 13
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 7 more

Search by objective public record fields.

Safety Study of OA-235i in Subjects With Nonalcoholic Steatohepatitis

Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

Alternate Day Fasting, Exercise, and NAFLD

Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial

Regulation of FGF21 by Nutritional Challenges

Efocipegtrutide (HM15211) in Adults With Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH)

The Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) Pediatric Patients

Effects of Mindfulness Based Stress Reduction Intervention in Patients With Non-alcoholic Fatty Liver Disease

Prediction of Severity of Liver Disease by a 13C Octanoate Breath Test (OBT)

A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD

Coronary Artery Disease and Its Association With Liver Steatosis Among HIV-Infected Persons

The Effect of Good Bacteria on Nonalcoholic Fatty Liver Disease in Diabetics

Behavioral Lifestyle Intervention for Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Adults

Dose Exploration Study of GSK4532990 in. Participants With NASH or Suspected NASH

NAFLD Pediatric Database 2

A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition

Safety and Efficacy of Solithromycin in the Treatment of Nonalcoholic Steatohepatitis Without Cirrhosis

Effects Of Exenatide On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Fatty Liver Disease

Early Intervention and Prevention of Non-Alcoholic Fatty Liver Disease in Adolescents

Vitamin E Dosing Study

A Preliminary Study to Evaluate Cysteamine Therapy in Human Subjects With Non-Alcoholic Steatohepatitis (NASH)

Hepatic Energy Fluxes in NASH and NAS Patients

Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States